LakeShore Biopharma Files 6-K Report
Ticker: LSBWF · Form: 6-K · Filed: Sep 4, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Sep 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: foreign-private-issuer, sec-filing, company-name-change
TL;DR
LakeShore Biopharma (ex-YS Biopharma) filed a 6-K, confirming 20-F annual reports. Beijing HQ.
AI Summary
LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on September 4, 2024. The filing is a report of a foreign private issuer for the month of September 2024, and it indicates that the company will file annual reports under Form 20-F. The company's principal executive offices are located in Beijing, PRC.
Why It Matters
This filing provides an update on LakeShore Biopharma's status as a foreign private issuer and its reporting obligations with the SEC.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new financial or operational information.
Key Numbers
- 001-41598 — SEC File Number (Identifies the specific filing series for the company)
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Registrant
- YS Biopharma Co., Ltd. (company) — Former Company Name
- YishengBio Co., Ltd (company) — Former Company Name
- 001-41598 (dollar_amount) — SEC File Number
- 20240904 (date) — Filing Date
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report information as a foreign private issuer for the month of September 2024.
What are the former names of LakeShore Biopharma Co., Ltd.?
The former names of LakeShore Biopharma Co., Ltd. are YS Biopharma Co., Ltd. and YishengBio Co., Ltd.
When did the company change its name from YS Biopharma Co., Ltd.?
The company changed its name from YS Biopharma Co., Ltd. on March 10, 2023.
Where are LakeShore Biopharma's principal executive offices located?
LakeShore Biopharma's principal executive offices are located at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.
Under which form will the registrant file its annual reports?
The registrant indicates it will file annual reports under cover of Form 20-F.
Filing Stats: 265 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-09-04 08:10:02
Filing Documents
- ea0213427-6k_lakeshore.htm (6-K) — 15KB
- ea021342701ex99-1_lakeshore.htm (EX-99.1) — 5KB
- 0001213900-24-075327.txt ( ) — 21KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE LakeShore Biopharma Co., Ltd (the “ Registrant ”) is filing this Form 6-K to furnish a press release issued on September 4, 2024, announcing its leadership transitions, which is furnished herewith as Exhibit 99.1. Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-279544 and File No. 333-273165 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. 1 EXHIBITS Exhibit No. Description 99.1 Press Release – LakeShore Biopharma Announces Leadership Transitions 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Rachel Yu Name: Rachel Yu Title: Director and Chief Financial Officer Date: September 4, 2024 3